Phase i trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Liver Neoplasms

abstract

  • The MTD of erlotinib with FOLFOX4 with or without bevacizumab is 100 mg daily. The regimen appeared to increase toxicity but showed activity in patients with CRC.

publication date

  • December 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3033228

Digital Object Identifier (DOI)

  • 10.3816/CCC.2010.n.043

PubMed ID

  • 21208844

Additional Document Info

start page

  • 297

end page

  • 304

volume

  • 9

number

  • 5